Advanced

miQ - a novel microRNA based diagnostic and prognostic tool for prostate cancer.

Larne, Olivia LU ; Martens-Uzunova, Elena ; Hagman, Zandra LU ; Edsjö, Anders LU ; Lippolis, Giuseppe LU ; Vredenbregt-van den Berg, Mirella S ; Bjartell, Anders LU ; Jenster, Guido and Ceder, Yvonne LU (2013) In International Journal of Cancer 132(12). p.2867-2875
Abstract
Today, the majority of prostate tumours are detected at early stages with uncertain prognosis. Therefore, we set out to identify early predictive markers of prostate cancer with aggressive progression characteristics. We measured the expression of microRNAs (miRNA) using qRT-PCR in FFPE prostatic tissue samples from a Swedish cohort of 49 patients with prostate cancer and 25 without cancer and found eight of 14 preselected miRNAs to discriminate between the two groups. Subsequently four discriminatory miRNAs were combined to a quota, denoted the miRNA index quote (miQ); ((miR-96-5p x miR-183-5p)/(miR-145-5p x miR221-5p)). The advantage using a quote is increased discrimination, no need for house-keepings, and most important it may be an... (More)
Today, the majority of prostate tumours are detected at early stages with uncertain prognosis. Therefore, we set out to identify early predictive markers of prostate cancer with aggressive progression characteristics. We measured the expression of microRNAs (miRNA) using qRT-PCR in FFPE prostatic tissue samples from a Swedish cohort of 49 patients with prostate cancer and 25 without cancer and found eight of 14 preselected miRNAs to discriminate between the two groups. Subsequently four discriminatory miRNAs were combined to a quota, denoted the miRNA index quote (miQ); ((miR-96-5p x miR-183-5p)/(miR-145-5p x miR221-5p)). The advantage using a quote is increased discrimination, no need for house-keepings, and most important it may be an advantage considering the heterogeneity of the disease. miQ was found to successfully predict diagnosis (p<0.0001) with high accuracy (AUC=0.931) that was verified in an independent Dutch cohort and three external cohorts, and significantly outperforming PSA. Importantly, miQ also has prognostic power to predict aggressiveness of tumours (AUC=0.895), metastatic statues (AUC=0.827), and overall survival (p=0.0013, Wilcoxon test HR=6.5, median survival 2 versus 5 years), verified in the Dutch cohort. In this preliminary study we propose that miQ has potential to be used as a clinical tool for prostate cancer diagnosis and as a prognostic marker of disease progression. © 2012 Wiley Periodicals, Inc. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
International Journal of Cancer
volume
132
issue
12
pages
2867 - 2875
publisher
John Wiley and Sons Inc.
external identifiers
  • wos:000317593100016
  • pmid:23184647
  • scopus:84876132672
  • pmid:23184647
ISSN
0020-7136
DOI
10.1002/ijc.27973
language
English
LU publication?
yes
additional info
The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Molecular Medicine (013031200), Division of Urological Cancers (013243420), Clinical Chemistry, Malmö (013016000)
id
aa1236ef-d5b0-4ae7-90ee-77319a00de06 (old id 3218469)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/23184647?dopt=Abstract
date added to LUP
2016-04-01 09:59:07
date last changed
2020-10-11 05:24:07
@article{aa1236ef-d5b0-4ae7-90ee-77319a00de06,
  abstract     = {Today, the majority of prostate tumours are detected at early stages with uncertain prognosis. Therefore, we set out to identify early predictive markers of prostate cancer with aggressive progression characteristics. We measured the expression of microRNAs (miRNA) using qRT-PCR in FFPE prostatic tissue samples from a Swedish cohort of 49 patients with prostate cancer and 25 without cancer and found eight of 14 preselected miRNAs to discriminate between the two groups. Subsequently four discriminatory miRNAs were combined to a quota, denoted the miRNA index quote (miQ); ((miR-96-5p x miR-183-5p)/(miR-145-5p x miR221-5p)). The advantage using a quote is increased discrimination, no need for house-keepings, and most important it may be an advantage considering the heterogeneity of the disease. miQ was found to successfully predict diagnosis (p&lt;0.0001) with high accuracy (AUC=0.931) that was verified in an independent Dutch cohort and three external cohorts, and significantly outperforming PSA. Importantly, miQ also has prognostic power to predict aggressiveness of tumours (AUC=0.895), metastatic statues (AUC=0.827), and overall survival (p=0.0013, Wilcoxon test HR=6.5, median survival 2 versus 5 years), verified in the Dutch cohort. In this preliminary study we propose that miQ has potential to be used as a clinical tool for prostate cancer diagnosis and as a prognostic marker of disease progression. © 2012 Wiley Periodicals, Inc.},
  author       = {Larne, Olivia and Martens-Uzunova, Elena and Hagman, Zandra and Edsjö, Anders and Lippolis, Giuseppe and Vredenbregt-van den Berg, Mirella S and Bjartell, Anders and Jenster, Guido and Ceder, Yvonne},
  issn         = {0020-7136},
  language     = {eng},
  number       = {12},
  pages        = {2867--2875},
  publisher    = {John Wiley and Sons Inc.},
  series       = {International Journal of Cancer},
  title        = {miQ - a novel microRNA based diagnostic and prognostic tool for prostate cancer.},
  url          = {http://dx.doi.org/10.1002/ijc.27973},
  doi          = {10.1002/ijc.27973},
  volume       = {132},
  year         = {2013},
}